Cagrilintide Peptide Intelligence Monograph | FIME

Long-Acting Amylin Analogue • Appetite Regulation • Obesity Research • Metabolic Science

Cagrilintide represents a different frontier in modern obesity research.

Rather than targeting the GLP-1 receptor, cagrilintide is a long-acting analogue of amylin—a naturally occurring peptide hormone involved in satiation, food intake, gastric emptying, and postprandial metabolism.

And unlike many compounds promoted within the peptide marketplace, cagrilintide has progressed into substantial randomized human clinical investigation, with clinically meaningful reductions in body weight demonstrated during pharmaceutical development.

The Founder’s Institute of Medicine & Education Cagrilintide Peptide Intelligence Monograph examines the science behind this emerging therapy while carefully separating promising clinical evidence from claims that extend beyond what the data currently establish.

Inside the Monograph

• What cagrilintide is and how it differs from native amylin
• Amylin physiology and receptor signaling
• Appetite, satiation, and energy-balance mechanisms
• Effects on gastric emptying and postprandial physiology
• Preclinical evidence
• Randomized human clinical evidence
• Cagrilintide monotherapy and weight reduction
• The important distinction between cagrilintide and CagriSema
• Safety and gastrointestinal tolerability
• Long-term evidence limitations
• Pharmaceutical-grade versus independently marketed products
• FDA and investigational status
• FIME evidence grading and clinical interpretation

FIME Evidence Perspective

Mechanistic Plausibility: Strong
Preclinical Evidence: Strong
Human Weight-Loss Evidence: Moderate to Strong
Human Safety Database: Moderate / Developing
Long-Term Safety: Developing
FDA-Approved Therapeutic Indication: None

Why This Monograph Matters

Cagrilintide demonstrates something important about the rapidly changing peptide landscape:

Some compounds are supported primarily by biological theory.

Others have promising animal evidence.

Cagrilintide has moved substantially further.

Randomized human trials demonstrate genuine clinical activity.

But meaningful human evidence does not erase the distinction between an investigational compound and an approved medication, nor does pharmaceutical clinical-trial evidence validate every commercially marketed product carrying the same name.

This monograph preserves those distinctions.

Mechanistically credible. Human studied. Clinically active. Still investigational.

The FIME Standard

Evidence over hype.
Science over claims.
Integrity over revenue.

Version 1.0 Final

Published by the Founder’s Institute of Medicine & Education

For professional education, scientific review, and evidence-based discussion. Not individualized medical advice, a prescription, or a treatment protocol. Cagrilintide remains investigational and does not have an FDA-approved therapeutic indication.